Gastroenterology
Volume 135, Issue 4 , Pages 1100-1105, October 2008

Polyp Size and Advanced Histology in Patients Undergoing Colonoscopy Screening: Implications for CT Colonography

Division of Gastroenterology and Hepatology, Oregon Health and Science University, Portland, Oregon

Received 25 March 2008; accepted 26 June 2008. published online 07 July 2008.

Background & Aims: Colorectal cancer screening with diagnostic imaging can detect polyps. The management of patients whose largest polyp is less than 10 mm is uncertain. The primary aim of this study was to determine rates of advanced histology in patients undergoing colorectal cancer screening whose largest polyp is 9 mm or less. Methods: Subjects include all asymptomatic adults receiving colonoscopy for screening during 2005 from 17 practice sites, which provide both colonoscopy and pathology reports to the Clinical Outcomes Research Initiative repository. Patients were classified by size of largest polyp. Advanced histology was defined as an adenoma with villous or serrated histology, high-grade dysplasia, or an invasive cancer. Risk factors for advanced histology were determined using Pearson χ2 and Fisher exact tests. Results: Among 13,992 asymptomatic patients who had screening colonoscopy, 6360 patients (45%) had polyps, with complete histology available in 5977 (94%) patients. The proportion with advanced histology was 1.7% in the 1- to 5-mm group, 6.6% in the 6- to 9-mm group, 30.6% in the greater than 10-mm group, and 72.1% in the tumor group. Distal location was associated with advanced histology in the 6- to 9-mm group (P = .04) and in the greater than 10-mm group (P = .002). Conclusions: One in 15 asymptomatic patients whose largest polyp is 6 to 9 mm will have advanced histology and would undergo surveillance at 3 years based on current guidelines. Because histology is necessary for this decision, most of these patients should be offered colonoscopy. Further study should determine whether patients whose largest polyp is 1–5 mm can be safely followed without polypectomy.

Abbreviations used in this paper: CORI, Clinical Outcomes Research Initiative, CTC, computer tomographic colonography

 

 Supported with funding from NIDDK UO1 DK57132 and R33-DK61778-01, and, in addition, the practice network (Clinical Outcomes Research Initiative) has received support from the following entities to support the infrastructure of the practice-based network: AstraZeneca, Bard International, Pentax USA, ProVation, Endosoft, GIVEN Imaging, and Ethicon; however, the commercial entities had no involvement in this research.

 Financial disclosure and conflicts of interest: Dr Lieberman is the executive director of the Clinical Outcomes Research Initiative (CORI), a nonprofit organization that receives funding from federal and industry sources. The CORI database is used in this study. This relationship has been reviewed and managed by the OHSU and Portland VAMC Conflict of Interest in Research Committee.

PII: S0016-5085(08)01203-1

doi:10.1053/j.gastro.2008.06.083

Refers to article:

  • Continuing Medical Education Exam 1: October 2008 , 09 September 2008

    Michael B. Wallace
    Gastroenterology October 2008 (Vol. 135, Issue 4, Pages 1379-1380)

Gastroenterology
Volume 135, Issue 4 , Pages 1100-1105, October 2008